Myeloid Leukemia disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: MYL006 MIFTS: 59	Myeloid Leukemia Categories: Blood diseases, Cancer diseases, Genetic diseases, Immune diseases, Rare diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Myeloid Leukemia

MalaCards integrated aliases for Myeloid Leukemia:

Name: Myeloid Leukemia ¹¹ ¹⁹ ²⁸ ⁵³ ¹⁴ ⁷¹ ⁷⁵

Myeloid Leukaemia ¹¹ ³¹ ³³

Myeloid Leukaemia, Unspecified, Without Mention of Remission ³³

Myeloid Granulocytic Leukaemia ¹¹

Myeloid Granulocytic Leukemia ¹¹

Non-Lymphocytic Leukemia ¹¹

Granulocytic Leukaemia ³³

Leukaemia Myelogenous ¹¹

Myelogenous Leukaemia ³³

Leukemia Myelogenous ¹¹

Leukemia, Myeloid ⁷⁵

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases Genetic diseases
Anatomical: Blood diseases Immune diseases

See all MalaCards categories (disease lists)

ICD10: ³¹

Neoplasms

Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue

Myeloid leukaemia

Myeloid leukaemia, unspecified

ICD11: ³³

Neoplasms

Neoplasms of haematopoietic or lymphoid tissues

Malignant haematopoietic neoplasms without further specification

Myeloid leukaemia

External Ids:

Disease Ontology ¹¹ DOID:8692

ICD9CM ³⁴ 205

MeSH ⁴³ D007951

NCIt ⁴⁹ C3172

SNOMED-CT ⁶⁸ 269631008

ICD10 ³¹ C92 C92.9

ICD11 ³³ 2018018546

UMLS ⁷¹ C0023470

Sources

Summaries for Myeloid Leukemia

GARD: ¹⁹ A clonal proliferation of myeloid cells and their precursors in the bone marrow, peripheral blood, and spleen. When the proliferating cells are immature myeloid cells and myeloblasts, it is called acute myeloid leukemia. When the proliferating myeloid cells are neutrophils, it is called chronic myelogenous leukemia.

MalaCards based summary: Myeloid Leukemia, also known as myeloid leukaemia, is related to leukemia, acute myeloid and leukemia, chronic myeloid. An important gene associated with Myeloid Leukemia is MIR99AHG (Mir-99a-Let-7c Cluster Host Gene), and among its related pathways/superpathways are HIF-1-alpha transcription factor network and Wnt/beta-catenin signaling pathway in leukemia. The drugs Nicotine and Mitoxantrone have been mentioned in the context of this disorder. Affiliated tissues include myeloid tissue, myeloid and bone marrow, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance

Disease Ontology: ¹¹ A leukemia that is located in myeloid tissue.

Wikipedia: ⁷⁵ Myeloid leukemia is a type of leukemia affecting myeloid... more...

Sources

Related Diseases for Myeloid Leukemia

Diseases in the Myeloid Leukemia family:

Leukemia, Acute Myeloid	Leukemia, Chronic Myeloid
Acute Myeloid Leukemia with T(6;9) (p23;q34.1)	Acute Myeloid Leukemia with T(8;21); (q22; Q22.1)
Acute Myeloid Leukemia with T(1;22)(p13;q13)	Subacute Myeloid Leukemia
Acute Myeloid Leukemia with T(9;11)(p22;q23)	Acute Myeloid Leukemia with T(9;22)(q34.1;q11.2)

Diseases related to Myeloid Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1754)

#	Related Disease	Score	Top Affiliating Genes
1	leukemia, acute myeloid	34.0	U2AF1 RUNX1T1 RUNX1 PICALM NUP98 MYH11
2	leukemia, chronic myeloid	33.9	U2AF1 RUNX1 NUP98 MCL1 HOXA9 GATA2
3	core binding factor acute myeloid leukemia	33.5	U2AF1 RUNX1T1 MYH11 FLT3
4	acute myelomonocytic leukemia	33.4	RUNX1 MYH11 FLT3 ETV6 CBFB
5	acute promyelocytic leukemia	33.4	U2AF1 RUNX1T1 RUNX1 NUP98 MYH11 MCL1
6	leukemia	33.3	U2AF1 RUNX1T1 RUNX1 PICALM NUP98 MYH11
7	atypical chronic myeloid leukemia, bcr-abl1 negative	33.3	U2AF1 FLT3 ETV6 ABL1
8	acute erythroid leukemia	33.3	U2AF1 GATA2 FLT3
9	childhood acute myeloid leukemia	33.1	U2AF1 RUNX1T1 NUP98 MYH11 FLT3
10	myelodysplastic syndrome	33.1	U2AF1 RUNX1T1 RUNX1 NUP98 MLF1 HOXA9
11	acute myeloid leukemia with bcr-abl1	32.9	FLT3 ABL1
12	acute myeloid leukemia with t(8;21)(q22;q22) translocation	32.9	RUNX1T1 RUNX1 FLT3
13	chronic myelomonocytic leukemia	32.7	U2AF1 RUNX1 GATA2 FLT3 ETV6 ABL1
14	childhood leukemia	32.7	U2AF1 RUNX1T1 NUP98 MYH11 FLT3 ETV6
15	myeloid sarcoma	32.7	U2AF1 RUNX1T1 FLT3
16	acute basophilic leukemia	32.7	U2AF1 ETV6 ABL1
17	platelet disorder, familial, with associated myeloid malignancy	32.7	RUNX1 ETV6
18	myeloid leukemia associated with down syndrome	32.6	RUNX1T1 MYH11
19	myeloproliferative syndrome, transient	32.6	U2AF1 GATA2 FLT3
20	acute leukemia	32.6	RUNX1T1 RUNX1 NUP98 HOXA9 GATA2 FLT3
21	acute biphenotypic leukemia	32.5	U2AF1 RUNX1T1 FLT3 ETV6 ABL1
22	essential thrombocythemia	32.5	U2AF1 FLT3 ETV6 ABL1
23	leukemia, acute monocytic	32.4	U2AF1 NUP98 FLT3
24	juvenile myelomonocytic leukemia	32.4	U2AF1 RUNX1 NUP98 HOXA9 GATA2 FLT3
25	myeloproliferative neoplasm	32.4	U2AF1 RUNX1 FLT3 ETV6 ABL1
26	hematologic cancer	32.4	U2AF1 RUNX1T1 RUNX1 PICALM NUP98 HOXA9
27	leukemia, acute lymphoblastic	32.3	U2AF1 RUNX1 PICALM MCL1 HOXA9 GATA2
28	myeloid and lymphoid neoplasms associated with pdgfra rearrangement	32.2	ETV6 ABL1
29	acute megakaryocytic leukemia	32.2	U2AF1 RUNX1T1 RUNX1 NUP98 MIR99AHG MIR100HG
30	myelofibrosis	32.0	U2AF1 RUNX1 GATA2 FLT3 ETV6
31	thrombocytopenia	31.9	U2AF1 RUNX1 GATA2 FLT3 ETV6 ABCB1
32	wilms tumor 1	31.9	U2AF1 RUNX1T1 FLT3 ABL1
33	leukemia, chronic lymphocytic	31.8	U2AF1 MCL1 FLT3 ABL1 ABCB1
34	refractory anemia with excess blasts	31.8	U2AF1 GATA2
35	b-lymphoblastic leukemia/lymphoma	31.6	U2AF1 FLT3 ETV6 ABL1
36	lymphoma, non-hodgkin, familial	31.6	U2AF1 MCL1 FLT3 ETV6 ABCB1
37	blood platelet disease	31.5	U2AF1 RUNX1 FLT3 ABL1
38	precursor t-cell acute lymphoblastic leukemia	31.5	PICALM NUP98 FLT3 ETV6 ABL1
39	gastrointestinal stromal tumor	31.5	U2AF1 MYH11 MCL1 FLT3 ETV6 ABL1
40	chronic leukemia	31.5	U2AF1 FLT3 ETV6 ABL1
41	childhood acute lymphocytic leukemia	31.4	RUNX1 MCL1 FLT3 ETV6 ABL1 ABCB1
42	myelodysplastic/myeloproliferative neoplasm	31.2	U2AF1 GATA2 FLT3 ETV6 ABL1
43	central nervous system leukemia	31.1	ETV6 ABL1
44	refractory cytopenia with multilineage dysplasia	31.0	U2AF1 GATA2
45	immunodeficiency 21	31.0	U2AF1 GATA2 FLT3
46	mantle cell lymphoma	31.0	U2AF1 MCL1 FLT3 ABL1
47	rasopathy	31.0	U2AF1 MYH11 GATA2 FLT3 ETV6 ABL1
48	severe congenital neutropenia	31.0	U2AF1 RUNX1 GATA2
49	neutrophilia, hereditary	31.0	U2AF1 FLT3
50	chronic eosinophilic leukemia	30.9	U2AF1 FLT3 ETV6 ABL1

Graphical network of the top 20 diseases related to Myeloid Leukemia:

Sources

Symptoms & Phenotypes for Myeloid Leukemia

GenomeRNAi Phenotypes related to Myeloid Leukemia according to GeneCards Suite gene sharing:

²⁵ (show all 25)

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Increased shRNA abundance (Z-score > 2)	GR00366-A-105	9.72	ABCB1 NUP98
2	Increased shRNA abundance (Z-score > 2)	GR00366-A-127	9.72	ABCB1
3	Increased shRNA abundance (Z-score > 2)	GR00366-A-129	9.72	HOXA9
4	Increased shRNA abundance (Z-score > 2)	GR00366-A-141	9.72	ABCB1
5	Increased shRNA abundance (Z-score > 2)	GR00366-A-151	9.72	ABL1
6	Increased shRNA abundance (Z-score > 2)	GR00366-A-157	9.72	ABL1
7	Increased shRNA abundance (Z-score > 2)	GR00366-A-181	9.72	NUP98
8	Increased shRNA abundance (Z-score > 2)	GR00366-A-186	9.72	CBFB HOXA9
9	Increased shRNA abundance (Z-score > 2)	GR00366-A-199	9.72	ABCB1
10	Increased shRNA abundance (Z-score > 2)	GR00366-A-212	9.72	HOXA9
11	Increased shRNA abundance (Z-score > 2)	GR00366-A-213	9.72	ABL1
12	Increased shRNA abundance (Z-score > 2)	GR00366-A-25	9.72	NUP98
13	Increased shRNA abundance (Z-score > 2)	GR00366-A-30	9.72	ABL1
14	Increased shRNA abundance (Z-score > 2)	GR00366-A-34	9.72	ABL1
15	Increased shRNA abundance (Z-score > 2)	GR00366-A-42	9.72	CBFB
16	Increased shRNA abundance (Z-score > 2)	GR00366-A-43	9.72	ABL1
17	Increased shRNA abundance (Z-score > 2)	GR00366-A-47	9.72	ABL1
18	Increased shRNA abundance (Z-score > 2)	GR00366-A-55	9.72	CBFB
19	Increased shRNA abundance (Z-score > 2)	GR00366-A-79	9.72	CBFB
20	Increased shRNA abundance (Z-score > 2)	GR00366-A-80	9.72	NUP98
21	Increased shRNA abundance (Z-score > 2)	GR00366-A-85	9.72	ABL1
22	Increased shRNA abundance (Z-score > 2)	GR00366-A-87	9.72	ABCB1
23	Increased shRNA abundance (Z-score > 2)	GR00366-A-88	9.72	CBFB
24	Increased shRNA abundance	GR00327-A	9.46	ERG FLT3 MCL1 MYH11
25	Synthetic lethal with vaccinia virus (VACV) infection	GR00362-A	9.26	GATA2 MCL1 MLF1 RUNX1T1

MGI Mouse Phenotypes related to Myeloid Leukemia:

⁴⁵ (show all 12)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	growth/size/body region	MP:0005378	10.32	ABCB1 ABL1 CBFA2T2 CBFB ERG ETV6
2	endocrine/exocrine gland	MP:0005379	10.23	ABCB1 ABL1 CBFA2T2 CBFB ERG ETV6
3	cellular	MP:0005384	10.18	ABL1 CBFA2T2 CBFB ERG ETV6 FLT3
4	normal	MP:0002873	10.1	ABL1 CBFB ERG ETV6 GATA2 MCL1
5	immune system	MP:0005387	10.1	ABCB1 ABL1 CBFA2T2 CBFB ERG ETV6
6	embryo	MP:0005380	10.09	ABL1 CBFB ERG ETV6 GATA2 MCL1
7	cardiovascular system	MP:0005385	10.06	ABCB1 ABL1 CBFB ERG ETV6 GATA2
8	hematopoietic system	MP:0005397	10	ABCB1 ABL1 CBFB ERG ETV6 FLT3
9	neoplasm	MP:0002006	9.99	CBFB ERG ETV6 FLT3 RUNX1 U2AF1
10	digestive/alimentary	MP:0005381	9.95	ABCB1 ABL1 CBFA2T2 CBFB ETV6 MYH11
11	mortality/aging	MP:0010768	9.83	ABCB1 ABL1 CBFA2T2 CBFB ERG ETV6
12	integument	MP:0010771	9.28	CBFB ERG ETV6 HOXA9 MYH11 PICALM

Sources

Drugs & Therapeutics for Myeloid Leukemia

Drugs for Myeloid Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 585)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Nicotine

Approved

Phase 4

54-11-5

942 89594

Mitoxantrone

Approved, Investigational

Phase 4

70476-82-3, 65271-80-9

4212

Cytarabine

Approved, Investigational

Phase 4

147-94-4

6253

Daunorubicin

Approved

Phase 4

20830-81-3

30323

Amsacrine

Approved, Investigational

Phase 4

51264-14-3

2179

Micafungin

Approved, Investigational

Phase 4

235114-32-6

477468

Lactitol

Approved, Investigational

Phase 4

585-86-4

157355

Benzocaine

Approved, Investigational

Phase 4

1994-09-7, 94-09-7

2337

Tannic acid

Approved

Phase 4

1401-55-4

16129878 16129778

Lenalidomide

Approved

Phase 4

191732-72-6

216326

Cholecalciferol

Approved, Nutraceutical, Vet_approved

Phase 4

67-97-0, 1406-16-2

5280795 10883523

Ergocalciferol

Approved, Nutraceutical

Phase 4

50-14-6

5280793

Calcifediol

Approved, Nutraceutical

Phase 4

19356-17-3

5283731

Vitamin D2

Phase 4

3249

Calciferol

Phase 4

Ergocalciferols

Phase 4

Hydroxycholecalciferols

Phase 4

HH-GV-678

Phase 4

Angiogenesis Inhibitors

Phase 4

Imatinib Mesylate

Phase 4

220127-57-1

Tin Fluorides

Phase 4

Iron

Approved

Phase 2, Phase 3

7439-89-6

29936

Coenzyme M

Approved, Investigational

Phase 3

3375-50-6

598 23662354

Dopamine

Approved

Phase 3

62-31-7, 51-61-6

681

Metoclopramide

Approved, Investigational

Phase 3

364-62-5

4168

Abatacept

Approved

Phase 3

332348-12-6

Lorazepam

Approved

Phase 3

846-49-1

3958

Sargramostim

Approved, Investigational

Phase 3

123774-72-1

Sirolimus

Approved, Investigational

Phase 3

53123-88-9

5284616 6436030

Adenosine

Approved, Investigational

Phase 3

58-61-7

60961

Mercaptopurine

Approved

Phase 3

50-44-2

667490

Levofloxacin

Approved, Investigational

Phase 3

100986-85-4

149096

Ofloxacin

Approved

Phase 3

82419-36-1

4583

Pentostatin

Approved, Investigational

Phase 3

53910-25-1

439693

Orange

Approved

Phase 2, Phase 3

Peginterferon alfa-2a

Approved, Investigational

Phase 3

198153-51-4

Captopril

Approved

Phase 3

62571-86-2

44093

Morphine

Approved, Investigational

Phase 3

57-27-2

5288826

Cobalt

Approved, Experimental, Withdrawn

Phase 3

7440-48-4

104729

Carvedilol

Approved, Investigational

Phase 3

72956-09-3

2585

Nalbuphine

Approved

Phase 3

20594-83-6

5311304

Enalaprilat

Approved

Phase 3

76420-72-9

6917719 5462501

Enalapril

Approved, Vet_approved

Phase 3

75847-73-3

40466924 5388962 5362032

Chlorhexidine

Approved, Vet_approved, Withdrawn

Phase 3

55-56-1

2713 9552079

Cladribine

Approved, Investigational

Phase 3

4291-63-8

20279

Nicotinamide

Approved, Investigational

Phase 3

98-92-0

936

Lomustine

Approved, Investigational

Phase 2, Phase 3

13010-47-4

3950

Picropodophyllin

Approved, Investigational

Phase 3

518-28-5, 477-47-4

10607 72435

Carboplatin

Approved

Phase 3

41575-94-4

10339178 38904

Coal tar

Approved

Phase 2, Phase 3

8007-45-2

Interventional clinical trials:

(show top 50) (show all 3307)

#	Name	Status	NCT ID	Phase	Drugs
1	A Randomized Comparison of Fludarabine in Combination With Cytarabine Versus High -Dose Cytarabine in Post-remission Therapy for AML1-ETO Acute Myeloid Leukemia	Unknown status	NCT02024308	Phase 4	Fludarabine;Cytarabine
2	Multicenter, PhaseⅣ, Open Label Trial of Nilotinib in Adult Patients Diagnosed Philadelphia Chromosome Positive(Ph+) Chronic Myeloid Leukemia in CP/AP Intolerant to Dasatinib	Unknown status	NCT02389920	Phase 4	Nilotinib
3	Early Tapering of Immunosuppressive Agents After Allogeneic Hematopoietic Stem Cell Transplantation Can Improve the Survival of Patients With Advanced Acute Myeloid Leukemia.	Unknown status	NCT03150134	Phase 4	Cyclosporine;routine reduction of immunosuppressive drugs(cyclosporine)
4	Low-dose Dasatinib as First-line Treatment for Chronic Myeloid Leukemia	Unknown status	NCT03216070	Phase 4	Dasatinib 50 MG
5	Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia	Unknown status	NCT02317159	Phase 4	Imatinib
6	Multicenter Randomised Clinical Trial in Acute Myeloid Leukemia Treatment Based on Three Anthracyclines, Comparing Two Types of Consolidation With Different ARA-C Doses Followed by One Year Maintenance	Unknown status	NCT01587430	Phase 4	high dose ARA-C;standard dose ARA-C
7	Decitabine for Myelodysplastic Syndromes and Acute Myeloid Leukemia Before Allogeneic Hematopoietic Cell Transplantation	Unknown status	NCT01806116	Phase 4	decitabine
8	Interferon for the Intervention of Molecular Relapse in t (8; 21) AML After Allo-HSCT	Unknown status	NCT02027064	Phase 4	Interferon-alpha
9	A Phase IV, Randomized Study to Evaluate the Safety and Efficacy of Idarubicin at Different Dosages Combined With Cytarabine as Induction Therapy for Newly Diagnosed Acute Myeloid Leukaemia	Unknown status	NCT02277847	Phase 4	Idarubicin(8mg/m2) and cytosine arabinoside;Idarubicin(10mg/m2), cytosine arabinoside
10	Treatment of Elderly Patients (>60 Years) With Acute Myeloblastic Leukemia or Advanced MDS (RAEB-T): An Open Randomized Study to Test the Efficacy of G-CSF-Priming and a Feasibility Trial of Dose-Reduced Allogeneic Transplantation and of Autologous Stem Cell Transplantation	Unknown status	NCT00199147	Phase 4	Cytarabine;Etoposide;Idarubicin;G-CSF;Fludarabine
11	G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor: a Prospective, Multicentre, Randomised Controlled Trial	Unknown status	NCT02933333	Phase 4
12	ASSESSMENT OF GH-IGF1 AXIS AND TO STUDY RESPONSE TO GH THERAPY IN CHILDREN WITH CML IN REMISSION HAVING GH DEFICIENCY	Unknown status	NCT01901666	Phase 4	Growth Hormone
13	A Phase 4 Study of Nilotinib in Korean Patients With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in Chronic Phase	Completed	NCT03332511	Phase 4	Nilotinib
14	An Open-label, Multicenter Study of Treatment With Nilotinib in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase	Completed	NCT00786812	Phase 4	Nilotinib
15	FLAT: Fludarabine, Cytarabine and Topotecan in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia	Completed	NCT00488709	Phase 4	Topotecan;Fludarabine;Cytarabine
16	A Clinical Trial to Evaluate the Efficacy and Safety of Recombinant Human Thrombopoietin in the Treatment of Thrombocytopenia After Chemotherapy in Acute Myeloid Leukemia	Completed	NCT02267993	Phase 4	recombinant human thrombopoietin
17	A SINGLE ARM, OPEN-LABEL, PHASE 4 STUDY EVALUATING QT INTERVAL, PHARMACOKINETICS, AND SAFETY OF GEMTUZUMAB OZOGAMICIN (MYLOTARG (TRADEMARKER)) AS A SINGLE-AGENT REGIMEN IN PATIENTS WITH RELAPSED OR REFRACTORY CD33-POSITIVE ACUTE MYELOID LEUKEMIA	Completed	NCT03727750	Phase 4	Gemtuzumab Ozogamicin
18	Glivec in Pediatric Chronic Myeloid Leukemia (CML)	Completed	NCT00845221	Phase 4	Imatinib mesylate 100 mg (Glivec)
19	Efficacy and Safety of Dasatinib in the First-line Treatment of Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP)	Completed	NCT04925141	Phase 4	Dasatinib Tablets
20	AML96 - Risk-Adapted and Randomized Postremission-Therapy for Adult Acute Myeloid Leukemia Patients. A Cooperative AML-Study of the German SHG-Study Group.	Completed	NCT00180115	Phase 4	Cytarabine Dosage
21	AML2003 - Randomized Comparison Between Standard-Therapy and Intensified Therapy for Adult Acute Myeloid Leukemia Patients <= 60 Years. A Prospective, Randomized, Multi-center Therapy-Optimizing-Study.	Completed	NCT00180102	Phase 4	Cytarabine vs. Cytarabine+Amsacrine+Mitoxantrone
22	PETHEMA LAM07: Prospective, Multicenter, Uncontrolled Cohort Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML)	Completed	NCT01041040	Phase 4	gemtuzumab
23	A Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib	Completed	NCT01660906	Phase 4	Dasatinib
24	An Open-label, Multicenter Study of Oral AMN107 (Nilotinib) in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Previously Enrolled to ENACT (CAMN107A2109) Trial	Completed	NCT01368523	Phase 4	nilotinib
25	A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 (Stoss Therapy) in Pediatric Patients Undergoing HSCT to Prevent Vitamin D Deficiency and Insufficiency During Transplant	Completed	NCT03176849	Phase 4
26	A Phase IV Single Arm, Multicenter, Open-label Study Assessing Deep Molecular Response in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive CML in Chronic Phase After Two Years of Treatment With Nilotinib 300mg BID	Completed	NCT02546674	Phase 4	Nilotinib
27	Open-Label, Multicenter, Effects of Remission Maintenance Therapy With Ceplene® , Given in Conjunction With Low-Dose Interleukin-2, on Immune Response and Minimal Residual Disease in Adult Patients With AML in First Complete Remission	Completed	NCT01347996	Phase 4	histamine dihydrochloride and IL-2
28	Incidence of Respiratory Viral Infections During AML Induction and Consolidation Chemotherapy	Completed	NCT01819792	Phase 4
29	Validation of Digital-PCR Analysis Through Programmed Imatinib Interruption in PCR Negative CML Patients (ISAV)	Completed	NCT01578213	Phase 4	Imatinib mesylate
30	Randomised Multicentre Phase IV Study to Compare Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec® in Combination With Interferon Alpha at Low Doses in the Treatment of Newly-Diagnosed Chronic-Phase Chronic Myeloid Leukaemia	Completed	NCT00390897	Phase 4	Glivec;Interferon
31	CRESCENDO (Compliance: Role Emerges for Success in CML: Evaluation aND Optimisation): A Prospective, Multi-center, Phase IV Study to Assess the Compliance in Patients With Philadelphia Chromosome-positive (Ph+) and/or BCR-ABL Positive Chronic Myelogenous Leukaemia (CML) Under Long-term Imatinib Therapy	Completed	NCT01243489	Phase 4
32	Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Ph+ CML	Completed	NCT00171899	Phase 4	imatinib mesylate
33	A Phase IV Study of Nilotinib in Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Who Have Suboptimal Molecular Response on Imatinib	Completed	NCT01043874	Phase 4	Nilotinib
34	An Exploratory Trial to Assess the Improvement of Chronic Low-grade Non-hematologic Adverse Events Experienced by Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Treated With Imatinib When Switched to Nilotinib Treatment	Completed	NCT00980018	Phase 4	Nilotinib
35	Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia	Completed	NCT00081926	Phase 4	Gleevec
36	A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)	Completed	NCT01227577	Phase 4	Nilotinib
37	FLAG-IDA Chemotherapy Induction Follow by Intensive Chemotherapy Postremission +/- Autologous Hemopoietic Stem Cell Transplantation or Bone Marrow Transplantation in Patients With High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia.	Completed	NCT00487448	Phase 4	Fludarabine;Cytarabine;G-CSF;Idarubicin
38	PETHEMA-LAM99:Treatment of the Acute Myeloblastic Leukaemia in Patients Over 65 Years	Completed	NCT00464217	Phase 4	ARA-C;Idarubicin;Leucomax
39	A Phase 4 Study of the Pharmacokinetics of Oral Posaconazole (SCH 56592) Among Patients With Compromised Gastrointestinal Function and at High Risk for Invasive Fungal Infection	Completed	NCT00686543	Phase 4	Posaconazole
40	A Phase IV Study of Corticosteroids As Prophylaxis for Infusion-Related Adverse Events to Mylotarg® in Patients With Acute Myelogenous Leukemia (AML)	Completed	NCT00304447	Phase 4	Mylotarg
41	A Randomized Open-Label Trial of Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome	Completed	NCT01200355	Phase 4	micafungin;posaconazole
42	Incidence of Invasive Fungal Disease in Patients Receiving Immunosuppressive Therapy, Intensive Chemotherapy or Reduced Intensity Haematopoietic Stem Cell Transplantation on Posaconazole Prophylaxis	Completed	NCT02875743	Phase 4	Posaconazole
43	Therapy of AML in Patients Older Than 60 Years: Randomized Comparison of a Double Induction With Daunorubicin and AraC (as Continuous Infusion) With a Double Induction With Mitoxantrone and Intermittent, Medium High Dose AraC	Completed	NCT00180167	Phase 4	randomization between two established Chemotherapies
44	Efficacy and Safety of Dasatinib 70 mg as First-Line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP)	Recruiting	NCT04155411	Phase 4	Dasatinib
45	The Efficacy and Safety of Switching to Flumatinib Versus Dasatinib After Imatinib-related Low-grade Adverse Events in Patients With Chronic Myeloid Leukemia in Chronic Phase: an Randomized Controlled Trial.	Recruiting	NCT04933526	Phase 4	Flumatinib;Dasatinib
46	A Double-blind , Randomized, Multicenter, Phase 4 Study to Evaluate Efficacy and Safety of Oral Flumatinib 400mg Versus 600mg in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.	Recruiting	NCT05353205	Phase 4	Flumatinib mesylate tablets (400mg);Flumatinib mesylate tablets (600mg)
47	Fludarabine and Cytarabine Versus High-dose Cytarabine in Consolidation Treatment of Core-bing Factor Acute Myeloid Leukemia: A Prospective, Multicenter, Randomized Study	Recruiting	NCT02926586	Phase 4	Fludarabine;Cytarabine
48	Efficacy and the Safety of Flumatinib in Treatment of CML-CP Patients With Ph+ Post Imatinib Failure	Recruiting	NCT04677439	Phase 4	Flumatinib
49	Evaluation of Antibody Response to High-Dose Seasonal Influenza Vaccination in Patients With Myeloid Malignancy Receiving Chemotherapy	Recruiting	NCT04484532	Phase 4
50	Immunogénicité de la Vaccination Anti-pneumococcique Dans la leucémie aiguë et le Lymphome Chez l'Adulte	Recruiting	NCT04460235	Phase 4	Prevenar13 Pneumo-23

Search NIH Clinical Center for Myeloid Leukemia

Inferred drug relations via UMLS ⁷¹ / NDF-RT ⁵⁰ :

dasatinib

imatinib

ponatinib

Sources

Genetic Tests for Myeloid Leukemia

Genetic tests related to Myeloid Leukemia:

#	Genetic test	Affiliating Genes
1	Myeloid Leukemia ²⁸

Sources

Anatomical Context for Myeloid Leukemia

Organs/tissues related to Myeloid Leukemia:

FMA: Myeloid Tissue

MalaCards : Myeloid, Bone Marrow, T Cells, Bone, Nk Cells, Spleen, Lymph Node

Sources

Publications for Myeloid Leukemia

Articles related to Myeloid Leukemia:

(show top 50) (show all 40916)

#	Title	Authors	PMID	Year
1	Clathrin assembly lymphoid myeloid leukemia-AF10-positive acute leukemias: a report of 2 cases with a review of the literature. ⁵³ ⁶²	Huh JY...Kong SY	20445327	2010
2	A prototype nonpeptidyl, hydrazone class, thrombopoietin receptor agonist, SB-559457, is toxic to primary human myeloid leukemia cells. ⁵³ ⁶²	Kalota A...Gewirtz AM	19880492	2010
3	Identification of two critically deleted regions within chromosome segment 7q35-q36 in EVI1 deregulated myeloid leukemia cell lines. ⁵³ ⁶²	De Weer A...Speleman F	20084277	2010
4	Transforming growth-interacting factor (TGIF) regulates proliferation and differentiation of human myeloid leukemia cells. ⁵³ ⁶²	Hamid R...Brandt SJ	19699159	2009
5	c-Jun N-terminal kinase 2 (JNK2) antagonizes the signaling of differentiation by JNK1 in human myeloid leukemia cells resistant to vitamin D. ⁵³ ⁶²	Chen-Deutsch X...Studzinski GP	19339050	2009
6	[Supportive therapies for myeloid leukemia including blood transfusion and growth factors]. ⁵³ ⁶²	Yao H...Maekawa T	19860196	2009
7	Inhibitors of poly ADP-ribose polymerase (PARP) induce apoptosis of myeloid leukemic cells: potential for therapy of myeloid leukemia and myelodysplastic syndromes. ⁵³ ⁶²	Gaymes TJ...Mufti GJ	19407318	2009
8	Retraction notice to "The retinoic acid receptor/CaMKII interaction: pharmacologic inhibition of CaMKII enhances the differentiation of myeloid leukemia cells" [Blood Cells Mol. Dis. 39 (2007) 307-315]. ⁵³ ⁶²		19388154	2009
9	[Abnormal expression of transcription factors LYL1 and LMO2 and interaction between them in myeloid leukemia]. ⁵³ ⁶²	Meng YS...Zhang YX	19671288	2009
10	[Apoptosis of human myeloid leukemia cell line HL-60 cells induced by siRNA targeting gene c-myc]. ⁵³ ⁶²	Liu TB...Chen ZZ	19379561	2009
11	Increased nuclear expression and transactivation of vitamin D receptor by the cardiotonic steroid bufalin in human myeloid leukemia cells. ⁵³ ⁶²	Amano Y...Makishima M	19429444	2009
12	DMNQ-S17 inhibits constitutive NF-kappaB activation leading to induction of apoptosis through the activation of caspase-3 in human myeloid leukemia U937 cells. ⁵³ ⁶²	Park MJ...Kim SH	18718843	2008
13	Expression profile of CREB knockdown in myeloid leukemia cells. ⁵³ ⁶²	Pellegrini M...Sakamoto KM	18801183	2008
14	Myeloid leukemia in children 4 years or older with Down syndrome often lacks GATA1 mutation and cytogenetics and risk of relapse are more akin to sporadic AML. ⁵³ ⁶²	Hasle H...Vyas P	18059480	2008
15	Spontaneous resolution of a single lesion of myeloid leukemia cutis in an infant: case report and discussion. ⁵³ ⁶²	D'Orazio JA...Moscow JA	18569848	2008
16	[Dihydroartemisinin down-regulates the expression of transferrin receptor in myeloid leukemia cells]. ⁵³ ⁶²	Wang Z...Zhou HJ	18822958	2008
17	Genomic structure, alternative splicing and expression of TG-interacting factor, in human myeloid leukemia blasts and cell lines. ⁵³ ⁶²	Hamid R...Brandt SJ	18455519	2008
18	Activated Ca2+/calmodulin-dependent protein kinase IIgamma is a critical regulator of myeloid leukemia cell proliferation. ⁵³ ⁶²	Si J...Collins SJ	18483256	2008
19	TGFbeta-mediated formation of pRb-E2F complexes in human myeloid leukemia cells. ⁵³ ⁶²	Hu XT	18294958	2008
20	Increased responsiveness to TLR2 and TLR4 ligands during dimethylsulfoxide-induced neutrophil-like differentiation of HL-60 myeloid leukemia cells. ⁵³ ⁶²	Shuto T...Kai H	17664007	2007
21	The retinoic acid receptor/CaMKII interaction: pharmacologic inhibition of CaMKII enhances the differentiation of myeloid leukemia cells. ⁵³ ⁶²	Si J...Collins SJ	17644368	2007
22	Inhibition of HuR and MMP-9 expression in macrophage-differentiated HL-60 myeloid leukemia cells by green tea polyphenol EGCg. ⁵³ ⁶²	Annabi B...Beliveau R	17081606	2007
23	Analysis of JAK3, JAK2, and C-MPL mutations in transient myeloproliferative disorder and myeloid leukemia of Down syndrome blasts in children with Down syndrome. ⁵³ ⁶²	Norton A...Vyas P	17644747	2007
24	CaMKII regulates retinoic acid receptor transcriptional activity and the differentiation of myeloid leukemia cells. ⁵³ ⁶²	Si J...Collins SJ	17431504	2007
25	Mast cell tryptase and microphthalmia transcription factor effectively discriminate cutaneous mast cell disease from myeloid leukemia cutis. ⁵³ ⁶²	Sundram UN...Natkunam Y	17381798	2007
26	Identification of novel nuclear localization signals of Drosophila myeloid leukemia factor. ⁵³ ⁶²	Sugano W...Yamaguchi M	18159124	2007
27	Re: Henschler R, Brennscheidt U, Mertelsmann R, and Herrmann F (1991). Induction of c-jun expression in the myeloid leukemia cell line KG-1 by 1-beta-D-arabinofuranosylcytosine. ⁵³ ⁶²		17213995	2007
28	Quantitative high-resolution CpG island mapping with Pyrosequencing reveals disease-specific methylation patterns of the CDKN2B gene in myelodysplastic syndrome and myeloid leukemia. ⁵³ ⁶²	Brakensiek K...Lehmann U	17095538	2007
29	Myeloid leukemia factor 1 associates with a novel heterogeneous nuclear ribonucleoprotein U-like molecule. ⁵³ ⁶²	Winteringham LN...Klinken SP	17008314	2006
30	Characterization of the Drosophila myeloid leukemia factor. ⁵³ ⁶²	Martin-Lanneree S...Plessis A	17121541	2006
31	Concomitant aberrant overexpression of RUNX1 and NCAM in regenerating bone marrow of myeloid leukemia of Down's syndrome. ⁵³ ⁶²	Langebrake C...Reinhardt D	17043020	2006
32	JS-K, a nitric oxide prodrug, induces cytochrome c release and caspase activation in HL-60 myeloid leukemia cells. ⁵³ ⁶²	Udupi V...Shami PJ	16439016	2006
33	Transgenic mice expressing the p75 CCAAT-displacement protein/Cut homeobox isoform develop a myeloproliferative disease-like myeloid leukemia. ⁵³ ⁶²	Cadieux C...Nepveu A	17018605	2006
34	[Apoptosis of myeloid leukemia cell line HL60 induced by Bortezomib, a proteasome inhibitor]. ⁵³ ⁶²	Fu YB...Zhou GB	17156654	2006
35	Inducer-and cell type-specific regulation of antiapoptotic MCL1 in myeloid leukemia and multiple myeloma cells exposed to differentiation-inducing or microtubule-disrupting agents. ⁵³ ⁶²	Vrana JA...Craig RW	16761109	2006
36	HIV-1 protease inhibitor ritonavir potentiates the effect of 1,25-dihydroxyvitamin D3 to induce growth arrest and differentiation of human myeloid leukemia cells via down-regulation of CYP24. ⁵³ ⁶²	Ikezoe T...Taguchi H	16457885	2006
37	[Detection of SOCS-1 mRNA expression by RT-PCR in the patients with myeloid leukemia]. ⁵³ ⁶²	Yang HP...Zhang DH	16928298	2006
38	ATRA can enhance apoptosis that is induced by Flt3 tyrosine kinase inhibition in Flt3-ITD positive cells. ⁵³ ⁶²	Scholl S...Hoffken K	16473406	2006
39	Cotylenin A-induced differentiation is independent of the transforming growth factor-beta signaling system in human myeloid leukemia HL-60 cells. ⁵³ ⁶²	Matsunawa M...Honma Y	16690533	2006
40	[EVI1 and its role in myelodysplastic syndrome, myeloid leukemia and other malignant diseases]. ⁵³ ⁶²	Fuchs O	16995417	2006
41	[Cytotoxicity of IFN-gamma-activated dendritic cells to freshly isolated acute myeloid leukemia cells]. ⁵³ ⁶²	Shi J...Ikeda K	16403283	2005
42	Decitabine activates specific caspases downstream of p73 in myeloid leukemia. ⁵³ ⁶²	Tamm I...Schmelz K	16193303	2005
43	Effect of clathrin assembly lymphoid myeloid leukemia protein depletion on clathrin coat formation. ⁵³ ⁶²	Meyerholz A...Ungewickell EJ	16262731	2005
44	Characterization of 6q abnormalities in childhood acute myeloid leukemia and identification of a novel t(6;11)(q24.1;p15.5) resulting in a NUP98-C6orf80 fusion in a case of acute megakaryoblastic leukemia. ⁵³ ⁶²	Tosi S...Harbott J	16028218	2005
45	Translational study of vitamin D differentiation therapy of myeloid leukemia: effects of the combination with a p38 MAPK inhibitor and an antioxidant. ⁵³ ⁶²	Wang Q...Studzinski GP	16107889	2005
46	CTCF regulates growth and erythroid differentiation of human myeloid leukemia cells. ⁵³ ⁶²	Torrano V...Delgado MD	15941718	2005
47	[Effect of GPI-PLD on adhesion function of bone marrow mononuclear cell from patients with myeloid leukemia and its mechanism]. ⁵³ ⁶²	Xiao GF...Jian ZF	15972122	2005
48	In vitro induction of myeloid leukemia-specific CD4 and CD8 T cells by CD40 ligand-activated B cells gene modified to express primary granule proteins. ⁵³ ⁶²	Fujiwara H...Barrett AJ	15958635	2005
49	5-Aza-2'-deoxycytidine induces p21WAF expression by demethylation of p73 leading to p53-independent apoptosis in myeloid leukemia. ⁵³ ⁶²	Schmelz K...Tamm I	15609309	2005
50	Myeloid leukemia factor 1 regulates p53 by suppressing COP1 via COP9 signalosome subunit 3. ⁵³ ⁶²	Yoneda-Kato N...Kato JY	15861129	2005

Sources

Genes for Myeloid Leukemia

Genes related to Myeloid Leukemia (0 elite genes):

(show top 50) (show all 95)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	MIR99AHG	Mir-99a-Let-7c Cluster Host Gene	RNA Gene	154.29	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	25027842
2	MIR100HG	Mir-100-Let-7a-2-Mir-125b-1 Cluster Host Gene	RNA Gene	154.1	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	25027842
3	FLT3	Fms Related Receptor Tyrosine Kinase 3	Protein Coding	67.61	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications Summaries Proteins Functions (show sections)	1384791 16209039 17202314 (more) 8896403 16473406 18182570 16320249 10194124 17943971
4	RUNX1	RUNX Family Transcription Factor 1	Protein Coding	66.24	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications Gene name Functions Domains & Families (show sections)	16995417 8643684 12461752 (more) 8585955 8667656 8585952 8412328 9794230 15856017 14551738 11568182 1570317 2115646 14506644 19767769 9473235 8049440 20084277 10675041 9447815 9209363 8639909 7598688 8321231 17968322 9498702 8545449 7530657 20363750 17043020 8663420 8637713 18815193 9067587 7624127 2108405 10484986
5	MLF1	Myeloid Leukemia Factor 1	Protein Coding	63.72	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Gene name Summaries Proteins Functions (show sections)	12354791 15861129 8570204 (more) 17008314 15122318 18159124 9595039 8661158 14506644 10393836 17121541 10523300
6	ABL1	ABL Proto-Oncogene 1, Non-Receptor Tyrosine Kinase	Protein Coding	62.49	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications Summaries Pathways & Interactions Functions (show sections)	12527798
7	RUNX1T1	RUNX1 Partner Transcriptional Co-Repressor 1	Protein Coding	52.52	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications Summaries Functions (show sections)	17572682 10675041
8	MCL1	MCL1 Apoptosis Regulator, BCL2 Family Member	Protein Coding	50.97	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Gene name Proteins Functions (show sections)	16761109 16806223 7682708 (more) 12788061 7835896 9671497 15286683
9	ERG	ETS Transcription Factor ERG	Protein Coding	47.91	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications Summaries Functions (show sections)	8234289 8187069 10779324 (more) 8545449
10	MYH11	Myosin Heavy Chain 11	Protein Coding	46.6	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications Summaries Functions (show sections)	16670269
11	CBFB	Core-Binding Factor Subunit Beta	Protein Coding	46.14	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications Summaries Functions (show sections)	16670269
12	HOXA9	Homeobox A9	Protein Coding	42.78	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications Functions (show sections)	10602420 10996203 14713950 (more) 11687616 17327400 15454493
13	NUP98	Nucleoporin 98 And 96 Precursor	Protein Coding	42.6	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications Functions (show sections)	18604245 15454493 16028218
14	ABCB1	ATP Binding Cassette Subfamily B Member 1	Protein Coding	41.87	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Pathways & Interactions Functions (show sections)	11689261 1364128 7910697 (more) 8704189 12010657 11809535 15958635
15	PICALM	Phosphatidylinositol Binding Clathrin Assembly Protein	Protein Coding	41.48	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Gene name Summaries (show sections)	12461747 9365832 11161218 (more) 14985334 18182011 8643484 12960147 16262731 15558718
16	GATA2	GATA Binding Protein 2	Protein Coding	41.42	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications Summaries (show sections)	7519472 10873593
17	U2AF1	U2 Small Nuclear RNA Auxiliary Factor 1	Protein Coding	40.9	DISEASES inferred ¹⁴ ¹⁴ GeneCards inferred via : Disorders Publications Summaries (show sections)
18	ETV6	ETS Variant Transcription Factor 6	Protein Coding	40.86	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications Functions (show sections)	9326218 9067587 11094079 (more) 8639909
19	MLF2	Myeloid Leukemia Factor 2	Protein Coding	40.64	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Gene name Proteins Functions (show sections)
20	CBFA2T2	CBFA2/RUNX1 Partner Transcriptional Co-Repressor 2	Protein Coding	40.29	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications Summaries Functions (show sections)
21	BCR	BCR Activator Of RhoGEF And GTPase	Protein Coding	39.78	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications Pathways & Interactions (show sections)	9671309
22	LIF	LIF Interleukin 6 Family Cytokine	Protein Coding	38.75	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Summaries Functions (show sections)	1908551 8564713 8462021 (more) 8632998 9606990 9811457 1645391 1906157 8023700 7515287 7538813 10613356 9240457
23	DNMT3A	DNA Methyltransferase 3 Alpha	Protein Coding	35.87	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications Summaries (show sections)
24	IDH1	Isocitrate Dehydrogenase (NADP(+)) 1	Protein Coding	35.65	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications Summaries (show sections)
25	CREBBP	CREB Binding Protein	Protein Coding	35.4	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Summaries Functions (show sections)	10970858 11561159
26	NPM1	Nucleophosmin 1	Protein Coding	34.93	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Summaries (show sections)	8570204 9595039 8661158 (more) 16501600 14506644 16671360
27	MYC	MYC Proto-Oncogene, BHLH Transcription Factor	Protein Coding	34.82	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Pathways & Interactions (show sections)	7500645 8810318 1901940 (more) 16185479 7731722 16714225 8462021 10822369 7882339 1743296 2196091 19379561 10036998 9178892 8896423 12496475 8668343 8139540 8518229 8034729 7488057 1906157 8424905 8231250
28	KIT	KIT Proto-Oncogene, Receptor Tyrosine Kinase	Protein Coding	34.77	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Pathways & Interactions (show sections)	1384791 17381798 10910906 (more) 19732733 11222388 7687773 7527672 1381238 9207920
29	RARA	Retinoic Acid Receptor Alpha	Protein Coding	33.97	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications (show sections)	15339853 1970118 9952315 (more) 11607822 16782888 10536188 10969805 16209039 1670759 17628022 19917671 8193361 7920173
30	MECOM	MDS1 And EVI1 Complex Locus	Protein Coding	33.66	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications (show sections)	8700545 17913523 10867128 (more) 12972028 14555651 16314052
31	BAALC	BAALC Binder Of MAP3K1 And KLF4	Protein Coding	33.55	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Summaries Expressions (show sections)
32	MEIS1	Meis Homeobox 1	Protein Coding	33.41	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Expressions (show sections)	9226379 17202314 10996203 (more) 14713950 15958703 10602420 7565694
33	KAT6A	Lysine Acetyltransferase 6A	Protein Coding	33.14	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Summaries Functions (show sections)
34	NUP214	Nucleoporin 214	Protein Coding	33.06	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications Summaries (show sections)
35	RUNX3	RUNX Family Transcription Factor 3	Protein Coding	32.84	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Gene name Domains & Families (show sections)
36	NSD1	Nuclear Receptor Binding SET Domain Protein 1	Protein Coding	32.55	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications Summaries (show sections)
37	RUNX2	RUNX Family Transcription Factor 2	Protein Coding	32.47	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Gene name Domains & Families (show sections)
38	WT1	WT1 Transcription Factor	Protein Coding	32.23	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Summaries (show sections)	9920756 11263329 11601276 (more) 15179007 8321047 16242775 18457871 9201704
39	CSF1R	Colony Stimulating Factor 1 Receptor	Protein Coding	32.17	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Pathways & Interactions (show sections)	18337452 8462021 2214871 (more) 1942539 1531307
40	PRDM16	PR/SET Domain 16	Protein Coding	31.73	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications Summaries (show sections)
41	CSF3R	Colony Stimulating Factor 3 Receptor	Protein Coding	31.61	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Proteins (show sections)	1701353 7509213 9815618 (more) 12788061 18687517 9711905 15370243 9548419
42	NCOA2	Nuclear Receptor Coactivator 2	Protein Coding	31.54	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Summaries Functions (show sections)
43	ASB2	Ankyrin Repeat And SOCS Box Containing 2	Protein Coding	31.45	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Summaries (show sections)	11682484 15590664 19376791
44	JAK2	Janus Kinase 2	Protein Coding	31.07	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications (show sections)	17644747 20042850
45	FUS	FUS RNA Binding Protein	Protein Coding	30.39	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications Functions (show sections)
46	FES	FES Proto-Oncogene, Tyrosine Kinase	Protein Coding	30.38	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications (show sections)	8634335 1984516 10706130 (more) 10567558 20030920 2088479
47	CHIC2	Cysteine Rich Hydrophobic Domain 2	Protein Coding	30.34	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications Summaries (show sections)
48	ELF4	E74 Like ETS Transcription Factor 4	Protein Coding	29.7	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications Expressions (show sections)
49	CCNA1	Cyclin A1	Protein Coding	29.25	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Expressions (show sections)	11381140 11090075 10590070
50	PCM1	Pericentriolar Material 1	Protein Coding	29.23	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications Summaries (show sections)

Sources

Variations for Myeloid Leukemia

Sources

Expression for Myeloid Leukemia

Search GEO for disease gene expression data for Myeloid Leukemia.

Sources

Pathways for Myeloid Leukemia

Pathways related to Myeloid Leukemia according to GeneCards Suite gene sharing:

(show all 11)

#	Super pathways	Score	Top Affiliating Genes
1	HIF-1-alpha transcription factor network ⁶¹	11.14	MCL1 GATA2 ABCB1
2	Wnt/beta-catenin signaling pathway in leukemia ⁷⁴	10.87	RUNX1T1 FLT3
3	Imatinib and chronic myeloid leukemia ⁷⁴	10.78	ABL1 ABCB1
4	Hematopoietic stem cell gene regulation by GABP alpha/beta complex ⁷⁴	10.76	FLT3 ETV6
5	Regulation of RUNX1 Expression and Activity ⁶⁶	10.66	RUNX1 CBFB
6	RUNX1 regulates transcription of genes involved in differentiation of myeloid cells ⁶⁶ Show member pathways RUNX2 regulates genes involved in differentiation of myeloid cells ⁶⁶	10.45	RUNX1 CBFB
7	RUNX1 regulates transcription of genes involved in BCR signaling ⁶⁶ Show member pathways RUNX1 regulates transcription of genes involved in interleukin signaling ⁶⁶	10.41	RUNX1 CBFB
8	RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs) ⁶⁶	10.32	RUNX1 CBFB
9	RUNX1 regulates transcription of genes involved in differentiation of keratinocytes ⁶⁶	10.16	RUNX1 CBFB
10	RUNX1 regulates transcription of genes involved in WNT signaling ⁶⁶	9.73	RUNX1 CBFB
11	RUNX1 regulates expression of components of tight junctions ⁶⁶	9.32	RUNX1 CBFB

Sources

GO Terms for Myeloid Leukemia

Cellular components related to Myeloid Leukemia according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	core-binding factor complex	GO:0016513	8.92	RUNX1 CBFB

Biological processes related to Myeloid Leukemia according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	regulation of DNA-templated transcription	GO:0006355	10.11	RUNX1 MLF2 MLF1 HOXA9 GATA2 ETV6
2	DNA-templated transcription	GO:0006351	10.03	RUNX1T1 MLF1 HOXA9 CBFA2T2
3	myeloid progenitor cell differentiation	GO:0002318	9.71	MLF1 FLT3
4	positive regulation of CD8-positive, alpha-beta T cell differentiation	GO:0043378	9.62	CBFB RUNX1
5	positive regulation of extracellular matrix organization	GO:1903055	9.56	RUNX1 ABL1
6	hemopoiesis	GO:0030097	9.5	RUNX1 PICALM GATA2 FLT3
7	negative regulation of CD4-positive, alpha-beta T cell differentiation	GO:0043371	9.46	RUNX1 CBFB
8	definitive hemopoiesis	GO:0060216	9.1	HOXA9 GATA2 CBFB